Timolol

New Delhi: A contract development and manufacturing organisation (CDMO) Akums Drugs & Pharmaceuticals has announced the launch of Ripasudil-Timolol combination therapy for glaucoma treatment . The new combination therapy offers a dual mechanism of action where Ripasudil enhances aqueous humor outflow through the trabecular meshwork and Timolol reduces aqueous humor production, the company said in a release. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments, it added. Commenting over the launch, Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., said, “This innovation integrates two distinct mechanisms of action to improve glaucoma treatment and our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected.” As per the company, by combining two medications into one product, potentially improved compliance and the single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management —patient adherence. The company release suggest that currently in India around 11.9 million people are affected with glaucoma and the condition stands as the third leading cause of vision impairment in India, after cataract and refractive errors By Online Bureau ,

Akums Drugs & Pharmaceuticals Ltd. has announced the launch of a pioneering Ripasudil-Timolol combination therapy for glaucoma treatment. This Drugs Controller General of India (DCGI)-approved product represents a significant advancement in ophthalmic care, with Akums becoming the first Indian CDMO to receive approval for this innovative formulation. Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden. The condition remains third among causes of vision impairment in India, after cataract and refractive errors. Also, Ocular hypertension is closely linked to glaucoma, many eye care professionals consider ocular hypertension to be a precursor or warning sign for glaucoma. Ocular hypertension refers to elevated pressure within the eye (intraocular pressure or IOP) that is higher than normal but without detectable damage to the optic nerve or visual field loss that would indicate glaucoma. While not everyone with ocular hypertension develops glaucoma, regular monitoring is crucial. Managing both conditions primarily involves lowering intraocular pressure to prevent further complications. The new combination therapy offers a dual mechanism of action for superior intraocular pressure (IOP) control: Ripasudil enhances aqueous humor outflow through the trabecular meshwork, while Timolol reduces aqueous humor production. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., said, "This innovation integrates two distinct mechanisms of action to improve glaucoma treatment. By enhancing efficacy and ease of use, we aim to offer a more practical and patient-friendly solution. Our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected. With a patient-first approach and a commitment to Make in India, we continue to develop solutions that are of high-quality, and aligned with global standards." The single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management—patient adherence. By combining two medications into one product, patients benefit from enhanced convenience and potentially improved compliance. "With the rising prevalence of glaucoma in India, introducing therapies that enhance efficacy and patient compliance is crucial," added Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd. "This launch marks a significant step in making high-quality and effective treatment more accessible," added Jain. Akums will utilise its manufacturing facilities to ensure consistent supply and the broad availability of this breakthrough therapy. With approximately 11.9 million people affected by glaucoma in India, this innovative combination addresses a critical healthcare need by providing an effective solution that simplifies treatment while potentially improving outcomes.